Abbott Announces First Quarter Financial Results and $200 Million U.S. Manufacturing Expansion

On April 16, Abott announced its financial results for the first quarter ended March 31, 2025      To further accelerate growth, Abbott plans to invest $200 million in expanding its U.S. manufacturing capabilities. This investment will enhance production capacities for key products, particularly in medical devices and nutrition. The company is also focusing on strengthening its Diabetes Care and heart failure product lines in the U.S., aligning with increasing consumer demand and healthcare trends. These investments are expected to foster continued growth in the U.S. market, improving product availability and meeting rising demand for Abbott's life-changing technologies.

Abbott’s U.S. manufacturing facilities continue to play a crucial role in meeting increased demand across its diversified product portfolio. The company attributed a significant portion of its domestic growth to these ongoing investments, which allow them to efficiently produce innovative and essential healthcare products.